Tychon Biosciences is advancing precision cancer immunotherapy through a novel approach that transforms a patient’s immune cells into a “PAR-T” cell trained to find and eliminate cancer cells.

 

Despite its promise as a new cancer treatment, clinical adoption of T-cell based immunotherapy has been slow due to a variety of shortcomings. Our therapy delivers on this promise by addressing these shortcomings with a novel approach.

Our PAR-T technology can be used as a primary therapy or in combination with other therapies, opening up enormous untapped potential to treat early and late-stage cancers.

DHFR_BisMTX_pic.png
 

Tychon Highlights

Safer.jpg

Safer

MINIMAL CYTOKINE ACTIVATION

Faster.jpg

FASTER

OFF-THE-SHELF THERAPY

Cheaper.jpg

CHEAPER

STANDARD PROTEIN MANUFACTURING

Paitent Friendly.jpg

PATIENT FRIENDLY

WEEKLY DOSING

Controllable2.jpg

CONTROLLABLE

THERAPY CAN BE “TURNED OFF” WITH COMMON ANTIBIOTIC